The LHC Cryomagnet Supports in Glass-Fiber Reinforced Epoxy: A Large Scale Industrial Production with High Reproducibility in Performance

por Poncet, A, Struik, M, Trigo, J, Parma, V
Publicado 2008

ST-segment elevation in a patient with cardiac lymphoma

por Guimarães, J. P., Trigo, J., Fonçalves, F., Moreira, J. I.
Publicado 2019

Thyroid cancer: SEOM clinical guidelines

por Trigo, J. M., Capdevila, J., Grande, E., Grau, J., Lianes, P.
Publicado 2014

A Phase I clinical and pharmacological study of cis-diamminedichloro(2-methylpyridine) platinum II (AMD473)

por Beale, P, Judson, I, O'Donnell, A, Trigo, J, Rees, C, Raynaud, F, Turner, A, Simmons, L, Etterley, L
Publicado 2003

Phase I/II trial of cilengitide with cetuximab, cisplatin and 5-fluorouracil in recurrent and/or metastatic squamous cell cancer of the head and neck: findings of the phase I part

por Vermorken, J B, Guigay, J, Mesia, R, Trigo, J M, Keilholz, U, Kerber, A, Bethe, U, Picard, M, Brummendorf, T H
Publicado 2011

SEOM clinical guidelines for the treatment of non-small cell lung cancer (2018)

por Majem, M., Juan, O., Insa, A., Reguart, N., Trigo, J. M., Carcereny, E., García-Campelo, R., García, Y., Guirado, M., Provencio, M.
Publicado 2018

SEOM clinical guidelines for the treatment of head and neck cancer (2020)

por Mesia, R., Iglesias, L., Lambea, J., Martínez-Trufero, J., Soria, A., Taberna, M., Trigo, J., Chaves, M., García-Castaño, A., Cruz, J.
Publicado 2021

Subcellular localisation of pMEK has a different prognosis in locally advanced head and neck cancer treated with concomitant radiochemotherapy

por Gomez-Millan, J., Pajares, B., Perez-Villa, L., Carnero, A., Alvarez, M., De Luque, V., Rivas, F., Trigo, J. M., Toledo, M. D., Alba, E., Medina, J. A.
Publicado 2016

Causes of death in patients with locally advanced head and neck cancer treated with radiotherapy and systemic therapy

por Zapata, I., Alvarez, M., Hidalgo, R., Pajares, B., Garcia-Anaya, M. J., Toledo, M. D., Trigo, J. M., Lupiañez-Perez, Y., Medina, J. A., Jaime Gomez-Millan, J.
Publicado 2019

A Phase I study of the angiogenesis inhibitor SU5416 (semaxanib) in solid tumours, incorporating dynamic contrast MR pharmacodynamic end points

por O'Donnell, A, Padhani, A, Hayes, C, Kakkar, A J, Leach, M, Trigo, J M, Scurr, M, Raynaud, F, Phillips, S, Aherne, W, Hardcastle, A, Workman, P, Hannah, A, Judson, I
Publicado 2005

Lurbinectedin, a selective inhibitor of oncogenic transcription, in patients with pretreated germline BRCA1/2 metastatic breast cancer: results from a phase II basket study

por Boni, V., Pistilli, B., Braña, I., Shapiro, G.I., Trigo, J., Moreno, V., Castellano, D., Fernández, C., Kahatt, C., Alfaro, V., Siguero, M., Zeaiter, A., Longo, F., Zaman, K., Antón, A., Paredes, A., Huidobro, G., Subbiah, V.
Publicado 2022

Treatment of cancer with oral drugs: a position statement by the Spanish Society of Medical Oncology (SEOM)

por Colomer, R., Alba, E., González-Martin, A., Paz-Ares, L., Martín, M., Llombart, A., Rodríguez Lescure, Á., Salvador, J., Albanell, J., Isla, D., Lomas, M., Rodríguez, C. A., Trigo, J. M., Germà, J. R., Bellmunt, J., Tabernero, J., Rosell, R., Aranda, E., Cubedo, R., Baselga, J.
Publicado 2010